Markets:

Overview

News

Currencies

International

Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

57.69 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Stocks Slip Ahead Of Fed Minutes, Nvidia Earnings ↗

February 21, 2024

Stocks are lower today, with the Nasdaq Composite Index (IXIC) leading the losses as investors reassess a potentially overvalued tech sector.

Via Talk Markets

Topics Economy Stocks

Crude Oil Moves Lower; Summit Therapeutics Shares Plummet ↗

February 20, 2024

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 200 points on Tuesday. The Dow traded down 0.18% to 38,557.86 while the NASDAQ fell 1.30% to 15,570.84. The...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 20, 2024

Via Benzinga

Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeutics Shares Tumbling Today? ↗

February 20, 2024

FDA places clinical hold on RAPT Therapeutics' Phase 2 trials for zelnecirnon in atopic dermatitis and asthma.

Via Benzinga

Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests ↗

February 20, 2024

The FDA put studies in eczema and asthma treatment on clinical hold.

Via Investor's Business Daily

Recap: RAPT Therapeutics Q3 Earnings ↗

November 13, 2023

Via Benzinga

Analyst Ratings for RAPT Therapeutics ↗

September 14, 2023

Via Benzinga

The Latest Analyst Ratings for RAPT Therapeutics ↗

August 09, 2023

Via Benzinga

Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 20, 2024

Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.

Via Benzinga

Dow Dips Over 100 Points; US Leading Economic Index Falls In January ↗

February 20, 2024

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1.5% on Tuesday. The Dow traded down 0.35% to 38,494.51 while the NASDAQ fell 1.51% to 15,537.95. The S&P 500...

Via Benzinga

Topics Stocks

Dow Rebounds; Nasdaq Drops Triple Digits ↗

February 20, 2024

Nvidia stock is sliding ahead of tomorrow's earnings report

Via Talk Markets

Topics Stocks

Analyst Ratings for RAPT Therapeutics ↗

June 05, 2023

Via Benzinga

Nasdaq Down 1%; Capital One Set To Buy Discover ↗

February 20, 2024

U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.05% to 38,607.53 while the NASDAQ fell...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 20, 2024

Via Benzinga

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

February 20, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

February 13, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 31, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

November 27, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

November 13, 2023

Company maintains strong cash position of $184.8 million

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

November 03, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

November 01, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

October 18, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio ↗

September 27, 2023

Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023 ↗

September 14, 2023

Via Benzinga

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

August 30, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

August 11, 2023

Company maintains strong cash position of $205 million

From RAPT Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023 ↗

August 09, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗

June 15, 2023

Via Benzinga

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

June 07, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

All News about RAPT Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today